Acta Med. 2026, 69: 65-71

https://doi.org/10.14712/18059694.2026.20

CTCAE-Guided Management of Cytotoxic Chemotherapy Toxicity in Uro-Oncology: A Contemporary Narrative Review

Minh Nguyet Tranováa,b, Oleg Izmaylova,b, Hanka Princlováa,b, Pavel Navrátila,b

aDepartment of Urology, University Hospital Hradec Králové, Hradec Králové, Czech Republic
bCharles University, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic

Received March 22, 2026
Accepted April 24, 2026

References

1. European Association of Urology. EAU Guidelines on Testicular Cancer. Edn. presented at the EAU Annual Congress London, 2026. Arnhem: EAU Guidelines Office; 2026. Available at: https://uroweb.org /guidelines/testicular-cancer (accessed March 22, 2026).
2. Gillessen S, Sauvé N, Collette L, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium. J Clin Oncol. 2021; 39: 1563–74. <https://doi.org/10.1200/JCO.20.03296> <PubMed>
3. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA. 2002; 99: 4592–5. <https://doi.org/10.1073/pnas.072067999> <PubMed>
4. European Association of Urology. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Edn. presented at the EAU Annual Congress London, 2026. Arnhem: EAU Guidelines Office; 2026. Available at: https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer (accessed March 22, 2026).
5. Pfister C, Gravis G, Fléchon A, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol. 2022; 40: 2013–22. <https://doi.org/10.1200/JCO.21.02051>
6. Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011; 12: 211–4. <https://doi.org/10.1016/S1470-2045(10)70275-8>
7. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 3068–77. <https://doi.org/10.1200/JCO.2000.18.17.3068>
8. European Association of Urology. EAU Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress London, 2026. Arnhem: EAU Guidelines Office; 2026. Available at: https://uroweb.org /guidelines/prostate-cancer (accessed March 22, 2026).
9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502–12. <https://doi.org/10.1056/NEJMoa040720>
10. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147–54. <https://doi.org/10.1016/S0140-6736(10)61389-X>
11. de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019; 381: 2506–18. <https://doi.org/10.1056/NEJMoa1911206>
12. Kimura S, Shigeta K, Tamura S, et al. Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022. Int J Clin Oncol. 2024; 29: 559–63. <https://doi.org/10.1007/s10147-024-02501-7>
13. European Association of Urology and American Society of Clinical Oncology. EAU-ASCO Guidelines on Penile Cancer. Edn. presented at the EAU Annual Congress London, 2026. Arnhem: EAU Guidelines Office; 2026. Available at: https://uroweb.org/guidelines/penile-cancer (accessed March 22, 2026).
14. Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010; 28: 3851–7. <https://doi.org/10.1200/JCO.2010.29.5477> <PubMed>
15. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13: 176–81. <https://doi.org/10.1016/S1053-4296(03)00031-6>
16. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 6.0 (MedDRA 28.0). Bethesda (MD): U.S. Department of Health and Human Services; 2025.
17. National Cancer Institute. NCI releases updated version of the Common Terminology Criteria for Adverse Events (CTCAE) reporting in clinical trials. Bethesda (MD): National Cancer Institute; 2026. Available at: https://dctd.cancer.gov/about/news-events/news/2026-news/ctcae-updated-version-6 (accessed June 10, 2026).
18. Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024; 9: 102195. <https://doi.org/10.1016/j.esmoop.2023.102195> <PubMed>
19. Sandherr M, Stemler J, Schalk E, et al. 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin in adult neutropenic patients with solid tumours and hematological malignancies. Lancet Reg Health Eur. 2025; 51: 101214. <https://doi.org/10.1016/j.lanepe.2025.101214> <PubMed>
20. Li J, Wu Y, Chen C, et al. A systematic review for prevention of cisplatin-induced nephrotoxicity using different hydration protocols and meta-analysis for magnesium hydrate supplementation. Clin Exp Nephrol. 2024; 28: 1–12. <https://doi.org/10.1007/s10157-023-02386-2>
21. Necchi A, Miceli R, Oualla K, et al. Effect of bleomycin administration on the development of pulmonary toxicity in patients with metastatic germ cell tumors receiving first-line chemotherapy: a meta-analysis of randomized studies. Clin Genitourin Cancer. 2017; 15: 213–220.e5. <https://doi.org/10.1016/j.clgc.2016.08.021>
22. Johnson K, Stoffel B, Schwitter M, et al. Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison. Support Care Cancer. 2024; 32: 554.
23. Coolbrandt A, Vancoille K, Dejaeger E, et al. Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer. Breast Cancer Res Treat. 2022; 192: 293–301. <https://doi.org/10.1007/s10549-021-06477-0>
24. Dale W, Klepin HD, Williams GR, et al. Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update. J Clin Oncol. 2023; 41: 4293–312. <https://doi.org/10.1200/JCO.23.00933> <PubMed>
25. Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019; 20: e200–7. <https://doi.org/10.1016/S1470-2045(19)30145-7>
26. Lustberg MB, Kuderer NM, Desai A, et al. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nat Rev Clin Oncol. 2023; 20: 527–42. <https://doi.org/10.1038/s41571-023-00776-9> <PubMed>
27. Maggiore U, Palmisano A, Buti S, et al. Chemotherapy, targeted therapy and immunotherapy: which drugs can be safely used in solid organ transplant recipients? Transpl Int. 2021; 34: 2442–58. <https://doi.org/10.1111/tri.14115> <PubMed>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive